A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer.

Bi, Zhao; Qiu, Peng-Fei; Zhang, Yue; Song, Xing-Guo; Chen, Peng; Xie, Li; Wang, Yong-Sheng; Song, Xian-Rang

Bi, Zhao; Qiu, Peng-Fei; Zhang, Yue; Song, Xing-Guo; Chen, Peng; Xie, Li; Wang, Yong-Sheng; Song, Xian-Rang.

Afiliación

Bi Z; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Qiu PF; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Zhang Y; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Song XG; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Chen P; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Xie L; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Wang YS; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Song XR; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

Front Oncol ; 11: 779140, 2021.

Article en En | MEDLINE | ID: mdl-34938660

Palabras clave

HER-2; LncRNA-AC009975.1; POTEH-AS1; biomarkers; breast cancer; lncRNA-AL390243.1; neoadjuvant therapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google